TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02109328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisertib
Description: SINGLE-ARM, SINGLE-DRUG PHASE: Alisertib will be given PO in a dosage of 50 mg BID for 7 Days (Days 1-7) of each 21 day treatment cycle.~In the randomized phase, Experimental arm will consist of the following drugs:~Alisertib will be given PO in a dosage of 40 mg twice daily on days 1-3, 8-10 and 15-17 of a 28 day cycle.~Paclitaxel: 60 mg/m2 over 60 minutes on Days 1, 8, and 15 in a 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Placebo will be given PO. Paclitaxel will be infused at the dose of 80 mg/m2 IV over a period of 60 minutes on Days 1, 8, and 15 in a 28-day cycle.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: Placebo will be given PO. Paclitaxel will be infused at the dose of 80 mg/m2 IV over a period of 60 minutes on Days 1, 8, and 15 in a 28-day cycle.
Study: NCT00214539

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bronchial Thermoplasty with the Alair System
Description: Alair treatment plus standard-of-care therapy of high dose inhaled corticosteroids and long acting beta-agonists with or without oral corticosteroids at a dose of ≤ 30 mg/day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Standard-of-care therapy of high dose inhaled corticosteroids and long acting beta-agonists with or without oral corticosteroids at a dose of ≤30 mg/day.
Study: NCT03740854

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pressure Controlled Ventilation
Description: Patients will be ventilated with a pressure level which supplies a tidal volume corresponding 8ml/kg, 12 breaths per minute, 1/2 inspiration/expiration ratio and %40 Fraction of Inspired Oxygen . These ventilator settings can be changed in order to adjust end tidal carbon dioxide and oxygen saturation levels.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Volume Controlled Ventilation
Description: Patients will be ventilated with a tidal volume which corresponds 8ml/kg, 12 breaths per minute, 1/2 inspirastion/expiration ratio and %40 Fraction of Inspired Oxygen . These ventilator settings can be changed in order to adjust end tidal carbon dioxide and oxygen saturation levels.
Study: NCT04494620

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Visual Inspection of Oral Cavity for Precancers and Cancer
Description: Participants were invited for 3 rounds of oral cavity cancer screening, conducted 3-years apart. Screening was conducted by health workers trained to perform visual inspection of the oral mucosa and identify potential precancerous lesions or oral cancer. Lesions found were referred to a weekly clinic for further evaluation by dentists and oncologists with experience in the diagnosis of oral lesions. Oral precancerous lesions were surgically excised whenever possible and those with confirmed oral cancer were referred for appropriate treatment with surgery, radiotherapy, and/or chemotherapy.
Study: NCT03439735

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endocrine Therapy and a CDK 4/6 inhibitor
Description: Participants with untreated metastatic disease receiving ET and a CDK 4/6 i as first line therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endocrine Therapy and a CDK 4/6 inhibitor
Description: Participants with untreated metastatic disease receiving ET and a CDK 4/6 i as first line therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endocrine Therapy and a CDK 4/6 inhibitor
Description: Participants initiating a CDK 4/6 i after progression on ET.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endocrine Therapy and a CDK 4/6 inhibitor
Description: Participants initiating a CDK 4/6 i after progression on ET.
Study: NCT03771300

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation
Description: This condition is based on the Progressive Muscle Relaxation.The relaxation program include training 16 muscle groups during the initial sessions, 7 muscle groups during the intermediate sessions, 4 muscle groups later and a only recall relaxation in the final session.This program is complemented with visualizations, as it was originally proposed by Jacobson (1938).
Study: NCT01861509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BP-C1
Description: BP-C1, 0.05% solution for injection; doses: 0.035 mg/kg body weight (0.07 mL/kg) intramuscularly once daily for 32 consecutive days
Study: NCT01123005

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET Scan
Description: radiation calculated per patient

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET Scan
Description: radiation calculated per patient

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EF5
Description: 10 mCi, IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EF5
Description: 10 mCi, IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbogen
Description: Calculated per patient

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dichloroacetate
Study: NCT03536637

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DMT310
Description: Topical Powder
Study: NCT02109328

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral tablets
Study: NCT05320029

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Disposable Powered Articulating Endoscopic Linear Cutter Stapler
Description: Using the Disposable Powered Articulating Endoscopic Linear Cutter Stapler according to routine treatment
Study: NCT03536637

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DMT310
Description: Topical Powder

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrogen Peroxide
Description: Liquid Diluent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrogen Peroxide
Description: Liquid Diluent

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Topical Powder

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo Topical Powder
Study: NCT04392856

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unified Protocol for Transdiagnostic Treatment of Emotional Disorders (UP)
Description: The Spanish Version of the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders for Homeless Women. The protocol contains five modules: (1) mindful emotion awareness, (2) cognitive flexibility, (3) countering emotional behaviors, (4) recognizing and confronting physical sensations, and (5) emotion exposures. This adaptation of Unified Protocol is organized in twelve sessions: Emotional disorders and emotional regulation; Motivation for change; Understanding the role of emotions; Mindful emotion awareness, Cognitive flexibility, Understanding and confronting physical sensations, Countering emotional behaviors, Emotional avoidance, Emotion exposure; Achievement recognition and look to the future; and Relapse prevention and closure.
Study: NCT03081026

Intervention type: DIAGNOSTIC_TEST
Intervention: Bilateral hip to ankle x-ray, exam and strength testing.
Description: Only an X-Ray is performed and reviewed to identify any growth disturbances.

Intervention type: DIAGNOSTIC_TEST
Intervention: Bilateral hip to ankle x-ray, exam and strength testing.
Description: Only an X-Ray is performed and reviewed to identify any growth disturbances.

Intervention type: DIAGNOSTIC_TEST
Intervention: Bilateral hip to ankle x-ray, exam and strength testing.
Description: Only an X-Ray is performed and reviewed to identify any growth disturbances.
Study: NCT06385483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO
Study: NCT05320029

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ECHELON Flex Powered Articulating Endoscopic Linear Cutters
Description: Using the ECHELON Flex Powered Articulating Endoscopic Linear Cutters according to routine treatment
Study: NCT03855735

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TeamBaby Online Communication Training (IG1) and TeamBaby Web-App Communication Training (IG2)
Description: The developed short manual for the teaching of different communication models competences will enable those who have been arbitrarily assigned to the intervention group and their relatives to develop secure communication competences (Phase 2). In Phase 3, the intervention group will have access to the digital app.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TeamBaby Online Communication Training (IG1) and TeamBaby Web-App Communication Training (IG2)
Description: The developed short manual for the teaching of different communication models competences will enable those who have been arbitrarily assigned to the intervention group and their relatives to develop secure communication competences (Phase 2). In Phase 3, the intervention group will have access to the digital app.
Study: NCT02921607

Intervention type: OTHER
Intervention: Observational group
Description: Participants will be asked to complete a questionnaire prior to discharge and 3 months later to follow up
Study: NCT01767922

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Extramel 10 mg - 140 UI SOD
Description: Subjects took one capsule of Extramel® 140 IU, or its corresponding placebo, daily over 12 weeks.~Each volunteer was seen for the 3 visits:~* visit V1, so-called inclusion visit (D0),~* visit V2 at 28 days, tolerance of +/- 3 days, (D28) and~* visit V3 at 84 days, tolerance of +/- 3 days, (D84).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Excipient only
Study: NCT03287388

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No Rocuronium
Description: Phase 1: The patient will undergo a routine MRI-abdomen without neuromuscular blockade: TOF ratio =1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium (moderate NMB)
Description: Phase 2: Rocuronium will be titrated to a moderate NMB (TOF 1-3), monitored by TOF-watch. When an adequate moderate NMB is achieved, the patient will undergo a second MRI-abdomen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium (deep NMB)
Description: Phase 3: The patient receives a bolus of 1.2 mg/kg rocuronium (adjusted to ideal body weight), to assure a deep or intense NMB (PTC 0-1). Then the patient will undergo the final, third MRI scan of the abdomen.
Study: NCT05300165

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Beer
Description: A daily beer will be consumed by the participants during a total of 6 weeks, changing every 2 weeks from alcohol-free lager beer, lager beer and dark beer
Study: NCT03800498

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DASH Education
Description: DASH health education about general knowledge of DASH diet Plan and lifestyle modification
Study: NCT01225029

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Amount of total fluids
Description: Term neonates receive either total fluids of 60 mL/kg/day (standard) or 40 mL/kg/day (restricted) on day of life (DOL) 1. Preterm neonates receive total fluids of 80 mL/kg/day (standard) or 60 mL/kg/day (restricted) on DOL 1. Each group receives an extra 20 mL/kg/day daily until total fluids of 150 mL/kg/day are achieved.
Study: NCT04524312

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total knee replacement
Description: Participant will undergo total knee replacement performed via anterior parapatellar approach with either Posterior-stabilized or retaining cruciate-retaining with dynamic congruence implant

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total knee replacement
Description: Participant will undergo total knee replacement performed via anterior parapatellar approach with either Posterior-stabilized or retaining cruciate-retaining with dynamic congruence implant

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Biomechanics
Description: Participants will be asked to perform biomechanical assesment before and following surgery at baseline, 6-8 weeks and 6-months postoperatively

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Biomechanics
Description: Participants will be asked to perform biomechanical assesment before and following surgery at baseline, 6-8 weeks and 6-months postoperatively

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NexGen Ps or Bioimplanti K-MOD implant
Description: Participant are randomly allocated to receive one of the NexGen PS or Biomplanti K-MOD total knee implant for treatment of end-stage knee osteoarthritis.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NexGen Ps or Bioimplanti K-MOD implant
Description: Participant are randomly allocated to receive one of the NexGen PS or Biomplanti K-MOD total knee implant for treatment of end-stage knee osteoarthritis.
Study: NCT00902642

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: an eight day university training course designed to integrating psychosocial factors in clinical practice on a patient level
Description: an eight day university training course on psychosocial factors for physical therapists
Study: NCT00649064

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ziprasidone
Description: Ziprasidone 40 mg capsules twice daily for the first 7 days followed by flexible dosing between 40 and 80 mg twice daily for the remaining 5 weeks.
Study: NCT00974571

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: montelukast sodium
Description: montelukast 10 mg tablet orally once daily at bedtime for 6 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: cetirizine
Description: cetirizine 10 mg tablet orally once daily at bedtime for 6 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: placebo
Description: placebo tablet orally once daily at bedtime for 6 weeks
Study: NCT01573780

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Smac mimetic TL32711
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy
Description: Optional correlative studies
Study: NCT03897790

Intervention type: OTHER
Intervention: Transcranial Doppler (DTC)
Description: Evaluation of Vasoconstrictor Vasoreactivity with Transcranial Doppler
Study: NCT04392856

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Same than experimental condition (UP), after it finishes
Description: The Spanish Version of the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders for Homeless Women. The protocol contains five modules: (1) mindful emotion awareness, (2) cognitive flexibility, (3) countering emotional behaviors, (4) recognizing and confronting physical sensations, and (5) emotion exposures. This adaptation of Unified Protocol is organized in twelve sessions: Emotional disorders and emotional regulation; Motivation for change; Understanding the role of emotions; Mindful emotion awareness, Cognitive flexibility, Understanding and confronting physical sensations, Countering emotional behaviors, Emotional avoidance, Emotion exposure; Achievement recognition and look to the future; and Relapse prevention and closure.
Study: NCT03929965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Anlotinib
Study: NCT04065789

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Carfilzomib on Days 1, 8, 15, of cycle numbers 1-9 and Days 1 and 15 only of cycle numbers 10-18, at a dose of 20 mg/m2 on day 1 of cycle 1; at dose of 56 mg/m2 on all subsequent once weekly dosing days. The quadruple regimen treatment will be administered for 18 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Daratumumab : 16 mg/Kg weekly for 8 weeks, then every 2 weeks for 16 weeks, and then every 4 weeks thereafter. The quadruple regimen treatment will be administered for 18 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide (25 mg), administered on days 1-21 of 28-day cycle.In frail patients, Lenalidomide dose will be reduced according to 15 mg . The quadruple regimen treatment will be administered for 18 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Patients will be treated with IV or oral dexamethasone (20 mg for fit and INT-FIT, 10 mg for frail), administered on Days 1-2, 8-9, 15-16, and 22-23 of each 28-day cycle for cycles 1-2 followed by weekly 20 mg dexamethasone on subsequent cycles; In frail patients, dexamethasone will be reduced to 10 mg . The quadruple regimen treatment will be administered for 18 cycles.
Study: NCT03718611

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR9001
Description: BR9001 is a test drug as generic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR9001
Description: BR9001 is a test drug as generic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR900A
Description: BR900A is a reference drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR900A
Description: BR900A is a reference drug
Study: NCT02332525

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oral Vibrational Stimulation
Description: Oral application of vibratory stimulus~: With the oral equipment, which is similar to the device generally used to prevent teeth grinding in dental clinics, 15-second vibratory and 15-second non-vibratory stimulus are given repeatedly for about 5 minutes using a vibrator that has a strength less than or equal to the vibratory stimulus of a smartphone (3.3V, 166Hz, maximum 180Hz). A stimulus of two times for 5 minutes, a total of at least 10 minutes is conducted for 10 days in a hospital or designated place.
Study: NCT04415580

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vestibular Rehabilitation (VR)
Description: VR consisted of two types of exercises, i.e., those for gaze stability and those for postural stability~* Gaze stability exercises The patients will perform the exercises while holding their gaze on a firm target (VORx1) during active horizontal and vertical head movements (one minute for each axis).~* Postural stability exercises March in Place Each patient will ask to get on a foam cushion of 10 cm in height and then will blindfold. Treadmill Training As preparation for training, all subjects underwent a 1-minute walk on treadmill with open eyes using preferred walking speed. Immediately after preparation, patients will blindfold and will ask to walk on treadmill without support of hands for 4 minutes.~When patients made the mistake of changing direction, the physiotherapist help them to keep the right position using verbal cues (e.g., you are turning left or right).
Study: NCT00804336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOM230
Description: Given subcutaneously twice a day for four weeks then given intramuscularly once every four weeks thereafter

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Description: Given orally once a day
Study: NCT03831711

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/MRI

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational software and coils in PET/MR scan
Description: General Electric (GE) Healthcare non-approved PET scanner coils and software
Study: NCT02620098

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Size Matters Handwriting Program
Description: The Size Matters Handwriting Program (Moskowitz, 2009) (SMHP) program incorporates principles grounded in motor learning theory, cognitive theory, and motivation theory. Children learn the importance of letter size by learning size 1 (capital and tall letters), size 2 (small letters) and size 3 letters (those that dive below the baseline) at different stages (Moskowitz, 2009). The intervention group received a total of 30 sessions of the SMHP, completed twice weekly over a 16 week period. Sessions lasted 30 minutes, and were led by an occupational therapist with training in the Size Matters Handwriting Program. All interventions were provided within the existing support classrooms. Each child had their own SMHP workbook.
Study: NCT01105507

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: canakinumab (company code: ACZ885D)
Study: NCT04415580

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Neurorehabilitation
Description: muscles stretching, active and assisted limbs mobilization, four limbs coordination exercises, balance training on instable platform and gait training
Study: NCT01906073

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intranasal fentanyl spray

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: slow release morphine
Study: NCT02334202

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy-Weight Gain
Description: Participants will have 1 individual pre-group session when each participant meets with the group leaders so that they can learn about each girl's significant relationships, set goals for the program, and so each girl can learn about group participation and format. Participants then will begin IPT-WG which is designed to decrease excessive weight gain among adolescents ages 12-17 years who are at risk for adult obesity. The IPT-WG program has been adapted to be appropriate for military dependents. The IPT-WG group meets for 12 consecutive, weekly group meetings and involves developing strategies for dealing with the problems girls struggle with that may lead to increased eating. At the 6th week of the group, the group leaders meet with each participant to review their progress and goals.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health Education
Description: The health education group will follow the HEY-Durham health program designed by researchers at Duke University. This program, designed to be delivered to youth attending community high schools, was adapted to a 12-week program (each with a 90 minute session). Girls will come in for a 1.5-hour group meeting once a week for 12 weeks (12 times total). Before beginning the group, girls will meet with group leaders to review each adolescent's family health history. The curriculum includes focus on various health topics, including avoiding alcohol, drug and tobacco use, nutrition and body image, nonviolent conflict resolution, sun safety, exercise, and domestic violence.
Study: NCT02232009

Intervention type: DEVICE
Group type: OTHER
Intervention: 3.0 T Neonatal MRI Scanner
Description: Eligible subjects will undergo neonatal MRI scanning procedures.